Hydroxychloroquine fails to prove artery benefit in rare clotting disorder
NCT ID NCT02595346
First seen Feb 05, 2026 · Last updated May 07, 2026 · Updated 11 times
Summary
This study looked at whether adding hydroxychloroquine to standard care could improve artery function in people with antiphospholipid syndrome, a condition that raises the risk of blood clots. The trial planned to enroll 25 adults, but was terminated early. Participants were randomly assigned to receive either hydroxychloroquine or a placebo alongside their usual treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME (APS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rouen University Hospital
Rouen, 76031, France
Conditions
Explore the condition pages connected to this study.